Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs AMITID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Irritable bowel syndrome,Enuresis
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Hepatic via CYP2D6, CYP2C19, CYP3A4; active metabolite nortriptyline.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
~93% bound to plasma proteins, primarily albumin.
90-95% bound primarily to albumin and α1-acid glycoprotein.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
3-5 L/kg; indicates extensive tissue distribution.
Oral: ~33% due to extensive first-pass metabolism.
Oral: 60-70%; Intravenous: 100%.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50%. GFR <15 m L/min: contraindicated or use with extreme caution, maximum 25 mg/day.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Not FDA-approved for use in children <12 years. For adolescent depression (off-label): start 25 mg/day, titrate up to 50–100 mg/day. Weight-based: 1–3 mg/kg/day, not to exceed 150 mg/day.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Start at 10–25 mg orally at bedtime; increase by 10–25 mg every 3–7 days to effective dose, typically 50–75 mg/day. Maximum 100 mg/day due to increased risk of anticholinergic effects, sedation, and orthostatic hypotension.
None
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Clinical worsening and suicide risk,Serotonin syndrome,Cardiovascular effects (QT prolongation, arrhythmia),Anticholinergic effects,Seizures,Angle-closure glaucoma,Urinary retention,Hepatic impairment,Hyponatremia
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Hypersensitivity to amitriptyline,Concomitant use with MAOIs (within 14 days),Acute recovery phase after myocardial infarction,Concurrent use of cisapride or other QT-prolonging drugs
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Tyramine-rich foods (aged cheese, cured meats, fermented products) should be limited due to risk of hypertensive crisis. Maintain adequate fluid intake to prevent constipation.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, based on observational studies. Absolute risk is low. Second and third trimesters: Chronic use may lead to neonatal adaptation syndrome (irritability, respiratory distress) and anticholinergic effects (e.g., constipation, urinary retention). Late third trimester exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN).
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Amitriptyline and its active metabolite nortriptyline are excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5–1.5. Relative infant dose is low (estimated <2% of weight-adjusted maternal dose). No adverse effects reported in infants followed prospectively. The American Academy of Pediatrics considers amitriptyline compatible with breastfeeding. However, monitor infant for sedation, poor feeding, and growth.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce serum drug concentrations. Therapeutic drug monitoring (if available) can guide dose adjustments; clinical response may require dose increases by 30–50% in the second and third trimesters. Avoid abrupt withdrawal; taper if discontinuing.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Amitriptyline is a tricyclic antidepressant with strong anticholinergic effects; monitor for QT prolongation, especially in elderly or those with cardiac disease. Start low (10-25 mg at bedtime) and titrate slowly. Avoid in recent MI, narrow-angle glaucoma, and urinary retention. Use with caution in seizure disorders.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take this medication at bedtime as it may cause drowsiness.,Avoid alcohol and other CNS depressants.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,May cause dry mouth, constipation, blurred vision; report severe side effects like fainting or irregular heartbeat.,Full therapeutic effect may take 2-4 weeks.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs AMITID, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. AMITID is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and AMITID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of AMITID is: 75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and AMITID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . AMITID is classified as Category C. First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.